DelveInsight has launched a new report on “Amyotrophic Lateral Sclerosis – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Amyotrophic Lateral Sclerosis Market Report:
- The prevalent population of ALS in the seven major markets was 71,628 in 2020 and is expected to grow at a CAGR of 0.6% during the study period.
- The diagnosed prevalent cases of ALS, in the United States, were 18,824 in 2020.
- ALS can be divided into C9ORF72, SOD1, other mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutations based on the types of mutations causing the condition. In the United States, the number of cases of C9ORF72, SOD1, other mutations (TARDBP, FUS, OPTN, ANG, etc.), and non-mutated/unidentified mutation was 6,118, 3,012, 1,506, and 8,188, respectively, in 2020.
- In 2020, the patients with the limb site of onset accounted for 2,502 cases, followed by 1,251 cases with the bulbar site of onset, 801 cases with a cervical site of onset, and 450 cases with other uncertain regions in Germany.
Key benefits of the report:
- Amyotrophic Lateral Sclerosis market report covers a descriptive overview and comprehensive insight of the Amyotrophic Lateral Sclerosis Epidemiology and Amyotrophic Lateral Sclerosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Amyotrophic Lateral Sclerosis market report provides insights on the current and emerging therapies.
- Amyotrophic Lateral Sclerosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Amyotrophic Lateral Sclerosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Amyotrophic Lateral Sclerosis market.
Amyotrophic Lateral Sclerosis Overview
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a group of rare neurological diseases that mainly involve the nerve cells (neurons), responsible for controlling voluntary muscle movement. Voluntary muscles produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS belongs to a broader group of disorders known as motor neuron diseases, which are caused by gradual deterioration and death of motor neurons. Motor neurons are nerve cells that extend from the brain to the spinal cord and to muscles throughout the body.
Amyotrophic Lateral Sclerosis Market
The dynamics of the Amyotrophic Lateral Sclerosis market are anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as Orion Pharma, Brainstorm-Cell Therapeutics, Orphazyme, MediciNova, Biogen, Biohaven Pharmaceutical, Prilenia Therapeutics, Apellis Pharmaceuticals, and others during the study period 2019-2032.
Learn more by requesting for sample @ Amyotrophic Lateral Sclerosis Market Landscape
Amyotrophic Lateral Sclerosis Pipeline Therapies and Key Companies
- Levosimendan: Orion Pharma
- NurOwn: Brainstorm-Cell Therapeutics
- Arimoclomol: Orphazyme
- Ibudilast: MediciNova
- Tofersen: Biogen
- Verdiperstat: Biohaven Pharmaceutical
- Pridopidine: Prilenia Therapeutics
- AMX0035: Amylyx
- Pegcetacoplan: Apellis Pharmaceuticals
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Amyotrophic Lateral Sclerosis Patient Share (%) Overview at a Glance
5. Amyotrophic Lateral Sclerosis Market Overview at a Glance
6. Amyotrophic Lateral Sclerosis Disease Background and Overview
7. Amyotrophic Lateral Sclerosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Amyotrophic Lateral Sclerosis
9. Amyotrophic Lateral Sclerosis Current Treatment and Medical Practices
10. Unmet Needs
11. Amyotrophic Lateral Sclerosis Emerging Therapies
12. Amyotrophic Lateral Sclerosis Market Outlook
13. Country-Wise Amyotrophic Lateral Sclerosis Market Analysis (2019–2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Amyotrophic Lateral Sclerosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Click here to read more about Amyotrophic Lateral Sclerosis Market Outlook 2032
Related Reports:
Amyotrophic Lateral Sclerosis Pipeline
Amyotrophic Lateral Sclerosis Epidemiology
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/